Amgen Suit Shows Limitations Of Biosimilar Safe Harbor
On Aug. 27, 2018, the United States District Court for the District of Delaware denied Hospira Inc.'s motion for judgment as a matter of law and found substantial evidence supported an...To view the full article, register now.
Already a subscriber? Click here to view full article